BioCryst Announces Positive Results from Two Ulodesine Phase 2 Trials in Patients with Gout
06:30 EDT 24 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced favorable
52-week safety results and sustained efficacy from the extension phase
of its randomized Phase
2b trial of ulodesine
(BCX4208) added to allopur...
Other Sources for this Article
BioCryst Pharmaceuticals
Investors:
Robert Bennett,
+1-919-859-7910
or
WCG
Media:
Catherine Kyroulis,
+1-212-301-7174
More From BioPortfolio on "BioCryst Announces Positive Results from Two Ulodesine Phase 2 Trials in Patients with Gout"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
